Does CAMRELIZUMAB Cause Reactive capillary endothelial proliferation? 41 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 41 reports of Reactive capillary endothelial proliferation have been filed in association with CAMRELIZUMAB. This represents 9.6% of all adverse event reports for CAMRELIZUMAB.
41
Reports of Reactive capillary endothelial proliferation with CAMRELIZUMAB
9.6%
of all CAMRELIZUMAB reports
12
Deaths
5
Hospitalizations
How Dangerous Is Reactive capillary endothelial proliferation From CAMRELIZUMAB?
Of the 41 reports, 12 (29.3%) resulted in death, 5 (12.2%) required hospitalization, and 1 (2.4%) were considered life-threatening.
Is Reactive capillary endothelial proliferation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAMRELIZUMAB. However, 41 reports have been filed with the FAERS database.
What Other Side Effects Does CAMRELIZUMAB Cause?
Myelosuppression (70)
Fatigue (60)
Nausea (60)
Vomiting (59)
Diarrhoea (54)
Anaemia (53)
Hypothyroidism (53)
Off label use (52)
Rash (50)
Thrombocytopenia (46)
What Other Drugs Cause Reactive capillary endothelial proliferation?
CAPECITABINE (19)
CISPLATIN (19)
DOCETAXEL\DOCETAXEL ANHYDROUS (17)
OXALIPLATIN (11)
ATEZOLIZUMAB (10)
BEVACIZUMAB (10)
PEMBROLIZUMAB (7)
SINTILIMAB (7)
TORIPALIMAB (6)
LENVATINIB (5)
Which CAMRELIZUMAB Alternatives Have Lower Reactive capillary endothelial proliferation Risk?
CAMRELIZUMAB vs CANAGLIFLOZIN
CAMRELIZUMAB vs CANAGLIFLOZIN\METFORMIN
CAMRELIZUMAB vs CANAKINUMAB
CAMRELIZUMAB vs CANDESARTAN
CAMRELIZUMAB vs CANDESARTAN CILEXETIL